RxDoctor Payments Data

Lisa Hoehn

Family · Flomaton, ALNPI 1124015847

Payments from drug & device makers

$1,557in general payments, 2019–2025

Across 61 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$274
  • Bayer$258
  • AstraZeneca$191
  • Amgen$152
  • Travere Therapeutics, Inc.$145
  • Novartis$134
  • plus $402 from 12 others

What the payments were for

  • Food & beverage$1,46194%
  • Education$966%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,557 in reported general payments places this provider in the 70th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$32,134
Medicare patients
273
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol127$88,513
JardianceEmpagliflozin93$54,659
VeltassaPatiromer Calcium Sorbitex23$25,268
KerendiaFinerenone27$24,918
Calcitriol96$1,401
Losartan Potassium110$973
Nifedipine ErNifedipine35$804
Hydralazine Hcl65$771
Amlodipine Besylate75$591
Famotidine41$554
Calcium Acetate17$528
Tamsulosin Hcl39$472
Carvedilol60$442
Valsartan11$323
Hydrochlorothiazide76$256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$191$88,513127 claims
Boehringer IngelheimJardiance$35$54,65993 claims
BayerKerendia$258$24,91827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,415 family providers in Alabama.

Other family in Flomaton

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →